MICHAEL COOPER: Open Payments
NPI 1386059277 · FESTUS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$607 in 39 payments from 12 companies in 2025. Trend: 2023 $1,109 · 2024 $22 · 2025 $607
Food & beverage: $607
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $169 |
| E.R. Squibb & Sons, L.L.C. | 3 | $70 |
| Alkermes, Inc. | 3 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $64 |
| Janssen Pharmaceuticals, Inc | 3 | $60 |
| Neurocrine BioSciences, Inc. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $29 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
Products named: VRAYLAR, ARISTADA, TRINTELLIX, REXULTI, COBENFY, SPRAVATO, INGREZZA, CAPLYTA.
Industry payments across MO — which companies pay providers there.
